Catherine Novack
Stock Analyst at JonesTrading
(4.52)
# 1,000
Out of 4,408 analysts
129
Total ratings
39.1%
Success rate
20.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Catherine Novack
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $135 | $49.91 | +170.51% | 1 | Jun 8, 2026 | |
| KRRO Korro Bio | Upgraded: Buy | $23 | $11.66 | +97.26% | 3 | May 8, 2026 | |
| DTIL Precision BioSciences | Initiated Coverage: Buy | $30 | $6.23 | +381.54% | 2 | Apr 16, 2026 | |
| TSX: MDNA Medicenna Therapeutics Corp. | Rated: Hold | n/a | $0.415 | - | 4 | Apr 10, 2026 | |
| RLYB Rallybio | Rated: Hold | n/a | $15.90 | - | 10 | Apr 10, 2026 | |
| WVE Wave Life Sciences | Maintained: Buy | $20 → $35 | $6.00 | +483.33% | 13 | Mar 26, 2026 | |
| IBIO iBio, Inc. | Initiated Coverage: Buy | $7 | $1.65 | +324.24% | 1 | Mar 2, 2026 | |
| LRMR Larimar Therapeutics | Maintained: Buy | $7 → $13 | $3.59 | +262.12% | 9 | Feb 24, 2026 | |
| PVLA Palvella Therapeutics | Maintained: Buy | $143 → $209 | $116.51 | +79.38% | 7 | Feb 24, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $85 → $97 | $35.07 | +176.61% | 15 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $43 | $36.03 | +19.34% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $33 | $3.84 | +759.38% | 1 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 | $26.72 | +8.53% | 8 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $9 | $1.76 | +411.36% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $18.73 | +60.17% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $1.56 | n/a | 3 | May 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $4.33 | n/a | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $6 | $3.98 | n/a | 8 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $1.98 | n/a | 6 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $0.87 | n/a | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.80 | n/a | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 → $60 | $1.69 | n/a | 4 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $5.83 | n/a | 4 | Nov 15, 2021 |
Spruce Biosciences
Jun 8, 2026
Initiated Coverage: Buy
Price Target: $135
Current: $49.91
Upside: +170.51%
Korro Bio
May 8, 2026
Upgraded: Buy
Price Target: $23
Current: $11.66
Upside: +97.26%
Precision BioSciences
Apr 16, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $6.23
Upside: +381.54%
Medicenna Therapeutics Corp.
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $0.415
Upside: -
Rallybio
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $15.90
Upside: -
Wave Life Sciences
Mar 26, 2026
Maintained: Buy
Price Target: $20 → $35
Current: $6.00
Upside: +483.33%
iBio, Inc.
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $1.65
Upside: +324.24%
Larimar Therapeutics
Feb 24, 2026
Maintained: Buy
Price Target: $7 → $13
Current: $3.59
Upside: +262.12%
Palvella Therapeutics
Feb 24, 2026
Maintained: Buy
Price Target: $143 → $209
Current: $116.51
Upside: +79.38%
Crinetics Pharmaceuticals
Jan 5, 2026
Maintained: Buy
Price Target: $85 → $97
Current: $35.07
Upside: +176.61%
Dec 23, 2025
Initiated Coverage: Buy
Price Target: $43
Current: $36.03
Upside: +19.34%
Sep 30, 2025
Initiated Coverage: Buy
Price Target: $33
Current: $3.84
Upside: +759.38%
Sep 25, 2025
Maintained: Buy
Price Target: $29
Current: $26.72
Upside: +8.53%
Aug 8, 2025
Maintained: Buy
Price Target: $6 → $9
Current: $1.76
Upside: +411.36%
Jun 25, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $18.73
Upside: +60.17%
May 17, 2025
Reiterated: Buy
Price Target: $11
Current: $1.56
Upside: n/a
May 15, 2025
Reiterated: Buy
Price Target: $12
Current: $4.33
Upside: n/a
May 13, 2025
Maintained: Buy
Price Target: $10 → $6
Current: $3.98
Upside: n/a
Nov 15, 2024
Reiterated: Buy
Price Target: $13
Current: $1.98
Upside: n/a
Nov 15, 2024
Reiterated: Buy
Price Target: $15
Current: $0.87
Upside: n/a
Oct 31, 2024
Downgraded: Hold
Price Target: n/a
Current: $2.80
Upside: n/a
Jun 3, 2024
Maintained: Buy
Price Target: $160 → $60
Current: $1.69
Upside: n/a
Nov 15, 2021
Downgraded: Hold
Price Target: n/a
Current: $5.83
Upside: n/a